Sökning: WFRF:(Hetland Merete) >
Short-term, interme...
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : Results from four Nordic countries
-
- Delcoigne, Benedicte (författare)
- Karolinska Institutet
-
- Ljung, Lotta, 1964- (författare)
- Karolinska Institutet,Umeå universitet,Reumatologi,Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
-
- Provan, Sella A. (författare)
- Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
-
visa fler...
-
- Glintborg, Bente (författare)
- The DANBIO Registry and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Lund Hetland, Merete (författare)
- The DANBIO Registry and Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Lederballe Grøn, Kathrine (författare)
- Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Glostrup, Denmark
-
- Peltomaa, Ritva (författare)
- Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
-
- Relas, Heikki (författare)
- Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
-
- Turesson, Carl (författare)
- Department of Rheumatology, Skåne University Hospital, Skåne, Lund, Sweden
-
- Gudbjornsson, Bjorn (författare)
- Faculty of Medicine, University Hospital of Iceland, Reykjavik, Iceland; Department of Rheumatology, Centre for Rheumatology Research, Reykjavik, Iceland
-
- Michelsen, Brigitte (författare)
- Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway
-
- Askling, Johan (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2022-03-22
- 2022
- Engelska.
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 81:6, s. 789-797
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice and to anchor these results with a general population comparator.Methods: Observational cohort study, with patients from Denmark, Finland, Norway and Sweden starting a bDMARD during 2008-2017. Time to first ACS was identified through register linkages. We calculated the 1-year, 2-year and 5-year incidence rates (IR) (on drug and ever since treatment start) and used Cox regression (HRs) to compare ACS incidences across treatments taking ACS risk factors into account. Analyses were further performed separately in subgroups defined by age, number of previous bDMARDs and history of cardiovascular disease. We also compared ACS incidences to an individually matched general population cohort.Results: 24 083 patients (75% women, mean age 56 years) contributing 40 850 treatment courses were included. During the maximum (5 years) follow-up (141 257 person-years (pyrs)), 780 ACS events occurred (crude IR 5.5 per 1000 pyrs). Overall, the incidence of ACS in RA was 80% higher than that in the general population. For all bDMARDs and follow-up definitions, HRs were close to 1 (etanercept as reference) with the exception of the 5-year risk window, where signals for abatacept, infliximab and rituximab were noted.Conclusion: The rate of ACS among patients with RA initiating bDMARDs remains elevated compared with the general population. As used in routine care, the short-term, intermediate-term and longer-term risks of ACS vary little across individual bDMARDs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- biological therapy
- cardiovascular diseases
- rheumatoid arthritis
- tumor necrosis factor inhibitors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Delcoigne, Bened ...
-
Ljung, Lotta, 19 ...
-
Provan, Sella A.
-
Glintborg, Bente
-
Lund Hetland, Me ...
-
Lederballe Grøn, ...
-
visa fler...
-
Peltomaa, Ritva
-
Relas, Heikki
-
Turesson, Carl
-
Gudbjornsson, Bj ...
-
Michelsen, Brigi ...
-
Askling, Johan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reumatologi och ...
- Artiklar i publikationen
-
Annals of the Rh ...
- Av lärosätet
-
Umeå universitet
-
Karolinska Institutet